|  | Chronic kidney disease | Chronic lung disease | Diabetes | Immunocompromised | Comorbidity free | Overall |
| --- | --- | --- | --- | --- | --- | --- |
|  | (N=71635) | (N=67407) | (N=142123) | (N=25571) | (N=1036476) | (N=1279209) |
| Sex |  |  |  |  |  |  |
| Female | 37893 (52.9%) | 43853 (65.1%) | 74083 (52.1%) | 14723 (57.6%) | 643895 (62.1%) | 780088 (61.0%) |
| Male | 33742 (47.1%) | 23554 (34.9%) | 68040 (47.9%) | 10848 (42.4%) | 392581 (37.9%) | 499121 (39.0%) |
| Race |  |  |  |  |  |  |
| White | 54834 (76.5%) | 54882 (81.4%) | 100253 (70.5%) | 19976 (78.1%) | 736989 (71.1%) | 918873 (71.8%) |
| Unknown | 2927 (4.1%) | 3518 (5.2%) | 11050 (7.8%) | 1409 (5.5%) | 152252 (14.7%) | 168151 (13.1%) |
| Black or African American | 11538 (16.1%) | 6372 (9.5%) | 22393 (15.8%) | 3266 (12.8%) | 82728 (8.0%) | 115876 (9.1%) |
| Asian | 2021 (2.8%) | 2130 (3.2%) | 7290 (5.1%) | 777 (3.0%) | 58535 (5.6%) | 68663 (5.4%) |
| American Indian or Alaska Native | 175 (0.2%) | 307 (0.5%) | 614 (0.4%) | 89 (0.3%) | 3408 (0.3%) | 4364 (0.3%) |
| Native Hawaiian or Other Pacific Islander | 140 (0.2%) | 198 (0.3%) | 523 (0.4%) | 54 (0.2%) | 2564 (0.2%) | 3282 (0.3%) |
| Ethnicity |  |  |  |  |  |  |
| Not Hispanic or Latino | 66858 (93.3%) | 62201 (92.3%) | 125158 (88.1%) | 23723 (92.8%) | 852089 (82.2%) | 1070876 (83.7%) |
| Hispanic or Latino | 3394 (4.7%) | 4015 (6.0%) | 13261 (9.3%) | 1343 (5.3%) | 104652 (10.1%) | 122808 (9.6%) |
| Unknown | 1383 (1.9%) | 1191 (1.8%) | 3704 (2.6%) | 505 (2.0%) | 79735 (7.7%) | 85525 (6.7%) |
| Age (years) |  |  |  |  |  |  |
| Mean (SD) | 72.4 (12.5) | 59.8 (16.8) | 64.8 (13.6) | 63.4 (15.3) | 51.4 (18.0) | 53.8 (18.2) |
| Median [Min, Max] | 73.9 [18.2, 99.0] | 61.7 [18.1, 99.0] | 66.3 [18.1, 98.7] | 65.6 [18.1, 98.8] | 51.8 [18.1, 98.9] | 55.3 [18.1, 99.0] |
| Age bracket |  |  |  |  |  |  |
| [18,20) | 24 (0.0%) | 509 (0.8%) | 161 (0.1%) | 98 (0.4%) | 21280 (2.1%) | 22050 (1.7%) |
| [20,25) | 103 (0.1%) | 1511 (2.2%) | 689 (0.5%) | 299 (1.2%) | 61147 (5.9%) | 63653 (5.0%) |
| [25,30) | 235 (0.3%) | 1855 (2.8%) | 1231 (0.9%) | 401 (1.6%) | 71461 (6.9%) | 74949 (5.9%) |
| [30,35) | 419 (0.6%) | 2490 (3.7%) | 2027 (1.4%) | 638 (2.5%) | 81660 (7.9%) | 86863 (6.8%) |
| [35,45) | 1671 (2.3%) | 7623 (11.3%) | 8471 (6.0%) | 1943 (7.6%) | 165399 (16.0%) | 183100 (14.3%) |
| [45,55) | 4162 (5.8%) | 10450 (15.5%) | 18850 (13.3%) | 3444 (13.5%) | 171968 (16.6%) | 203745 (15.9%) |
| [55,65) | 10197 (14.2%) | 14236 (21.1%) | 33956 (23.9%) | 5532 (21.6%) | 186716 (18.0%) | 239245 (18.7%) |
| [65,75) | 22132 (30.9%) | 15962 (23.7%) | 43758 (30.8%) | 7251 (28.4%) | 177219 (17.1%) | 245762 (19.2%) |
| [75,85) | 22304 (31.1%) | 9528 (14.1%) | 25996 (18.3%) | 4588 (17.9%) | 78791 (7.6%) | 123472 (9.7%) |
| [85,Inf) | 10388 (14.5%) | 3243 (4.8%) | 6984 (4.9%) | 1377 (5.4%) | 20835 (2.0%) | 36370 (2.8%) |
| Breakthrough COVID-19 infection |  |  |  |  |  |  |
| Breakthrough COVID | 1985 (2.8%) | 2385 (3.5%) | 3825 (2.7%) | 1161 (4.5%) | 16202 (1.6%) | 23174 (1.8%) |
| No breakthrough | 69650 (97.2%) | 65022 (96.5%) | 138298 (97.3%) | 24410 (95.5%) | 1020274 (98.4%) | 1256035 (98.2%) |
| Hospitalization following breakthrough |  |  |  |  |  |  |
| Hospitalized | 877 (1.2%) | 435 (0.6%) | 1098 (0.8%) | 414 (1.6%) | 1778 (0.2%) | 3577 (0.3%) |
| Not hospitalized | 70758 (98.8%) | 66972 (99.4%) | 141025 (99.2%) | 25157 (98.4%) | 1034698 (99.8%) | 1275632 (99.7%) |